Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Health and Drug Alerts

Propofol: contraindicated for sedation of pediatric intensive care patients

Eric Wooltorton
CMAJ September 03, 2002 167 (5) 507;
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Propofol — an anesthetic agent1 — may cause life-threatening adverse events when used to sedate critically ill children.2 The problem was first noted in 1992, when a report was published of 5 children with croup or bronchiolitis in an intensive care unit (ICU) who were sedated with propofol and subsequently died of metabolic acidosis and myocardial failure.3

Subsequently termed “propofol syndrome,” sporadic cases were described in the literature, including a report in 1998 of 18 critically ill pediatric patients who experienced bradycardia, asystole, severe metabolic acidosis, lipemia, hepatomegaly and rhabdomyolysis.4 In 2001 the US Food and Drug Administration communicated that pediatric ICU patients given the drug for sedation as part of a randomized controlled trial had higher death rates than those who received standard anesthetic agents.5,6 Health Canada recently reported that 6 serious postmarketing adverse events, including 3 deaths, had occurred in children receiving propofol in an ICU setting.2 All patients experienced metabolic acidosis, hemodynamic instability and cardiac conduction abnormalities.2 Canadian product monographs for propofol infusions are now being updated to indicate that the agent is contraindicated for the sedation of children receiving intensive care.

The drug: Propofol is a chemically distinct hypnotic agent administered intravenously for the induction and maintenance of general anesthesia or for sedation in both adults and children.1 The rapid onset and offset of action and the relative lack of cumulative effects have made it popular.7 The 2002 Compendium of Pharmaceuticals and Specialties states that propofol is indicated for anesthesia in children 3 years of age and older but that it is not recommended for sedation in children under the age of 18 years, either during surgical or diagnostic procedures or in the ICU.1

Results of biochemical analyses throughout the clinical course of a pediatric patient who experienced propofol syndrome and recovered after hemodialysis suggest that impaired fatty acid oxidation at the level of the mitochondria may be responsible for this syndrome.8 However, patient-specific factors predicting this adverse effect, and the reason for its relative absence in adults, are not yet known.

What to do: The propofol syndrome has occurred in critically ill children receiving the drug for sedation. In such patients, alternative sedatives should be used. The syndrome may be less common when the drug is used in less critically ill pediatric patients for short periods (e.g., for procedural sedation or for the induction and maintenance of general anesthesia).9,10 Unfortunately, large randomized controlled trials evaluating the drug's safety for this indication are lacking.11 The known and theoretical risks of propofol should be explained to parents.

Many drugs licensed for use in adults are used “off label” in children.12 The serious, life-threatening postmarketing adverse events seen with propofol reinforce that significant harm can come from off-label use of agents whose pediatric safety profile is incomplete.

Eric Wooltorton CMAJ

References

  1. 1.↵
    Propofol injection [product monograph]. In: Compendium of pharmaceuticals and specialties. Ottawa: Canadian Pharmacist's Association; 2002.
  2. 2.↵
    Propofol contraindicated for sedation in pediatric patients receiving intensive care. Ottawa: Health Canada; 2002 July 10. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/tpd/propofol_pediatric2_e.html (accessed 2002 Aug 6).
  3. 3.↵
    Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-6.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth 1998;8:491-9.
    OpenUrlCrossRefPubMed
  5. 5.↵
    FDA issues warning on propofol (Diprivan). CMAJ 2001;164(11):1608.
    OpenUrlFREE Full Text
  6. 6.↵
    Diprivan [propofol]. In: Medwatch 2001 Safety Information Summaries. Washington: US Food and Drug Administration; 2001 Apr 25. Available: www.fda.gov/medwatch/safety/2001/safety01.htm#dipriv (accessed 2002 Aug 6).
  7. 7.↵
    Hancock SW, Morgan-Hughes NJ. Propofol sedation in children [electronic letter]. BMJ 2000 Nov 9. Available: bmj.com/cgi/eletters/321/7269 /1093 #10738 (accessed 2002 Aug 6).
  8. 8.↵
    Wolf A, Weir P, Segar P, Stone J, Shield J. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001;357:606-7.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Reed MD, Blumer JL. Propofol bashing: The time to stop is now! Crit Care Med 1996;24:175-6.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Vardi A, Salem Y, Padeh S, Paret G, Barzilay Z. Is propofol safe for procedural sedation in children? A prospective evaluation of propofol versus ketamine in pediatric critical care. Crit Care Med 2002;30:1231-6.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Hatch DJ. Propofol-infusion syndrome in children. Lancet 1999;353:1117-8.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Choonara I. Clinical trials of medicines in children. BMJ 2000;321:1093-4.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 167, Issue 5
3 Sep 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Propofol: contraindicated for sedation of pediatric intensive care patients
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Propofol: contraindicated for sedation of pediatric intensive care patients
Eric Wooltorton
CMAJ Sep 2002, 167 (5) 507;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Propofol: contraindicated for sedation of pediatric intensive care patients
Eric Wooltorton
CMAJ Sep 2002, 167 (5) 507;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Propofol syndrome in children
  • Propofol syndrome in children
  • Propofol syndrome in children
  • Google Scholar

More in this TOC Section

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Pediatrics
    • Drugs: adverse reactions
    • Anesthesia & analgesia

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire